Noninfringement Defense Based on Prior Commercial Use Under 35 U.S.C. § 273 Must Be Timely and Expressly Pleaded

May 9, 2024

Reading Time : 2 min

The district court in a patent infringement case granted plaintiff’s ex parte request to strike defendant’s prior use defense under 35 U.S.C. § 273. Because defendant failed to plead the defense and did not raise it until just prior to the final pretrial conference, the court struck the defense as untimely.

Amended by the America Invents Act in 2011, Section 273 provides a noninfringement defense to a claim for patent infringement based on the defendant’s prior commercial use of the claimed product. This defense is separate and distinct from an invalidity defense based on prior public use under Section 102(a). And to rely on it, the defendant must introduce clear and convincing evidence that the defendant commercially used a product that meets the claim limitations prior to the effective filing date of the claims.

Here, after the court granted plaintiff’s motion for summary judgment of no invalidity, defendant sought to raise a defense under Section 273. In response, plaintiff filed an ex parte request to strike the defense as untimely. According to plaintiff, the first-time defendant had raised the defense was in its pretrial Memorandum of Contentions of Fact and Law. Defendant argued that it had pleaded facts consistent with a prior use defense. But the court struck the defense, holding that defendant had to actually plead a prior commercial use defense to infringement and could not merely rely on background facts consistent with the defense to establish that the defense had been timely raised. The court noted that the statutory language of Section 273(f), which requires a reasonable basis for asserting the defense, also suggests that the defense must be actually pleaded. 

Relatedly, the court granted-in-part plaintiff’s motion in limine seeking to exclude defendant’s arguments and evidence comparing its own products to prior art devices. Defendant argued that these comparisons were relevant to plaintiff’s infringement claims, defendant’s prior use defense to infringement and damages. Because the court struck defendant’s purported prior commercial use defense as untimely and concluded that the evidence was irrelevant to infringement, the court excluded defendant’s evidence and arguments suggesting that its own products practice the prior art. The court did, however, refrain from excluding defendant’s arguments and evidence for the narrow purpose of potentially rebutting plaintiff’s willful infringement arguments by showing that defendant had a good faith belief that the asserted patents were invalid. 

Practice Tip: Although some defendants may be hesitant to rely on Section 273, which requires clear and convincing evidence that the accused product meets the claim limitations, the defense may still be useful where, for example, infringement is not contested. But if a defendant wants to assert the prior commercial use defense, the defense should be raised expressly in the pleadings to avoid waiver. Alleging facts that are merely consistent with the defense will not be sufficient. 

Delta T LLC v. MacroAir Technologies, Inc., Case Nos. 5:20-cv-00728-GW-GJS, D.I. 399 (C.D. Cal. Apr. 19, 2024).

Share This Insight

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.